Description
Key Clinical Benefits:
- Promotes natural GH and IGF-1 production
- Reduces visceral (abdominal) fat
- Enhances lean muscle definition
- Supports cognitive clarity and brain health
1. Falutz J, et al. (2007)
Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. This pivotal Phase III randomized controlled trial demonstrated that tesamorelin significantly reduced visceral adipose tissue while maintaining a favorable safety profile.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/18057338/
DOI:
https://doi.org/10.1056/NEJMoa064066
2. Falutz J, et al. (2008)
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. An extension study evaluating long term efficacy and safety over 52 weeks.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/18690162/
DOI:
https://doi.org/10.1097/QAD.0b013e32830b3e4d
3. Stanley TL, et al. (2014)
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. Published in JAMA, this study found that tesamorelin reduced both visceral adipose tissue and liver fat in people with HIV.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/25038357/
DOI:
https://doi.org/10.1001/jama.2014.8334
4. Grunfeld C, et al. (2011)
Tesamorelin.
A concise review published in Nature Reviews Drug Discovery discussing the mechanism of action, approval, and clinical development of tesamorelin.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/21283099/
DOI:
https://doi.org/10.1038/nrd3362
5. Clinical Review Report (CADTH)
A comprehensive review of the Phase III clinical trials, efficacy, safety, and regulatory assessment.
https://www.ncbi.nlm.nih.gov/books/NBK539127/